品质为先。

     

APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

新闻

最新资讯

  • 2023 - 09 - 20

    European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

    Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
  • 2023 - 09 - 13

    美纳里尼亚太与安斯泰来签订独家授权协议在中国台湾和部分东南亚市场商业化施觅福®

    新加坡2023年9月13日 /美通社/ -- 美纳里尼亚太公司与安斯泰来制药集团(简称“安斯泰来”)达成长期独家许可合作关系,在中国台湾开发、生产和商业化口服Janus激酶(JAK)抑制剂施觅福® 50 mg和100 mg片剂(通用名:氢溴酸吡西替尼,peficitinib hydrobromide),用于治疗类风湿性关节炎。施觅福® 已在中国台湾获得批准,其物质组成专利保护期至2032年。
  • 2023 - 07 - 21

    Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

    Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
  • 2023 - 07 - 06

    Fair Play Menarini International Awards, the champions of Fair Play cast their spell on the audience in Fiesole

    FLORENCE, July 6th, 2023 – Yesterday evening, the grand finale of the XXVII edition of the Menarini International Fair Play Awards was warmly greeted by over one thousand spectators at the Roman Theatre in Fiesole. The event, organised by the Menarini Fair Play Foundation and focused on the culture of fair play and respect in sport, drew to a close for the first time on this magnificent stage. Headlining the event were the winners of the 2023 edition, internationally renowned sports legends, shining examples of a healthy approach to competition, both in sporting events and life.
  • 2023 - 07 - 03

    美纳里尼第二代抗组胺药力敏能®(比拉斯汀片)在中国获批,引领荨麻疹高品质诊疗新时代

    2023年6月26日,中国上海 -- 美纳里尼今日宣布,旗下第二代非镇静性的长效抗组胺药物力敏能®(通用名:比拉斯汀片)正式获国家药品监督管理局(NMPA)批准上市,适用于12岁及以上青少年和成年人荨麻疹的对症治疗。力敏能®获批后,将为中国慢性特发性荨麻疹患者带来新的治疗选择,以更高品质的诊疗优势满足患者的未尽之需,引领中国荨麻疹诊疗新时代。
  • 2023 - 06 - 20

    Fair Play Menarini International Awards announces the winners of the XXVII edition at CONI

    ROME, June 19th, 2023 - The winners of the XXVII annual Fair Play Menarini International Awards are no longer a secret. This morning at the CONI Hall of Honour, a press conference was held to present the 2023 edition of the awards, scheduled from July 3rd to 5th in Florence and Fiesole. In the presence of Giovanni Malagò, President of the Italian National Olympic Committee (CONI), the Fair Play Menarini Foundation unveiled the list of this year’s winners to be celebrated at the event which has promoted the values of ethics, loyalty and respect through the example of Italian and international sport legends since 1997.

媒体联系人

我们积极寻找合作伙伴,与我们共同致力于解决高度未满足的疾病,并使此类患者的未来从此不同。